Home/Filings/4/0001193125-25-230359
4//SEC Filing

Abate Kristin 4

Accession 0001193125-25-230359

CIK 0001503802other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 4:56 PM ET

Size

5.3 KB

Accession

0001193125-25-230359

Insider Transaction Report

Form 4
Period: 2025-10-01
Abate Kristin
Chief Accounting Officer
Transactions
  • Sale

    Common Stock

    2025-10-01$6.30/sh362$2,27910,046 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
  • [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.19 to $6.30, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0002045943

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:56 PM ET
Size
5.3 KB